Pulmonx Reports Second Quarter 2026 Financial Results
Rhea-AI Summary
Pulmonx (Nasdaq:LUNG) reported second quarter 2026 revenue of $22.8 million, down 5% year over year, or 6% on a constant currency basis. U.S. revenue was $14.2 million (-4% YoY) and international revenue was $8.6 million (-6% YoY, -9% constant currency). According to Pulmonx, international revenue excluding China grew 12% year over year (9% constant currency) as China sales paused pending renewal of a registration certificate.
Gross profit was $17.7 million with a record 78% gross margin, up from 72% a year earlier. Operating expenses declined 16% to $26.8 million. Net loss improved to $10.1 million (or $0.24 per share) from $15.2 million, and adjusted EBITDA loss narrowed to $5.1 million from $8.4 million. Cash and cash equivalents were $55.8 million on June 30, 2026. Pulmonx reaffirmed 2026 revenue guidance of $90–$92 million, now expects full-year gross margin of about 76%, operating expenses of $109–$111 million, and projects a $23 million reduction in cash, cash equivalents, and marketable securities for 2026.
Positive
- Revenue guidance reaffirmed at $90–$92 million for full year 2026
- Record gross margin of 78% in Q2 2026, up from 72% in 2025
- Operating expenses reduced 16% year over year to $26.8 million
- Net loss reduced 34% to $10.1 million or $0.24 per share
- Adjusted EBITDA loss reduced 39% to $5.1 million in Q2 2026
- International revenue excluding China grew 12.2% year over year in Q2 2026
Negative
- Total Q2 2026 revenue declined 4.6% year over year to $22.8 million
- U.S. revenue decreased 3.8% year over year to $14.2 million
- International revenue fell 6.0% year over year, or 9.0% on a constant currency basis
- No China sales in Q2 2026 while awaiting renewal of registration certificate
- Cash and cash equivalents decreased to $55.8 million from $69.8 million at year-end 2025
- 2026 cash, cash equivalents, and marketable securities projected to decline by about $23 million
News Explained
At
Sources and calculations
- Pulmonx second-quarter 2026 results release (2026-07-29)
- Pulmonx first-quarter 2026 fundamentals (2026Q1)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $61,572,000 / ($10,097,000 / 90) = [object Object]
Market reaction after 2Q26 earnings report: LUNG +20.00%
Following this news, LUNG has gained 20.00%, reflecting a significant positive market reaction. Our momentum scanner has triggered 5 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.50.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Q1 earnings report | Positive | +6.7% | Margin stability, ex-China growth, debt refinancing, and reaffirmed full-year guidance |
| Mar 04 | Q4 earnings report | Positive | +11.8% | Annual revenue growth, credit facility, cost restructuring, and 2026 guidance |
| Nov 12 | Q3 earnings report | Negative | -18.9% | Reduced full-year guidance followed slower-than-expected U.S. revenue conversion |
| Jul 30 | Q2 earnings report | Negative | -41.6% | Lowered revenue guidance after slower-than-expected U.S. revenue conversion |
| Apr 30 | Q1 earnings report | Positive | -21.9% | Revenue growth, reaffirmed guidance, and improved international performance |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-tagged events produced four aligned and one divergent reactions, while the five-event average move was -12.79%.
Key Terms
constant currency financial
adjusted ebitda financial
gaap financial
stock-based compensation financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2026 ended June 30, 2026.
Recent Highlights
- Achieved worldwide revenue of
$22.8 million in the second quarter of 2026, a5% decrease over the same period last year and a decrease of6% on a constant currency basis - Delivered
$14.2 million in U.S. revenue in the second quarter of 2026, representing a4% year-over-year decrease - Delivered
$8.6 million in international revenue in the second quarter of 2026, representing a6% year-over-year decrease and a decrease of9% on a constant currency basis; excluding China, year-over-year international revenue increased12% and9% on a constant currency basis - Achieved record gross margin of
78% in the second quarter of 2026 - Demonstrated operating leverage from cost realignment efforts, reducing net loss by
34% and adjusted EBITDA loss by39% in the second quarter of 2026 as compared to the same period last year
“We are pleased with the progress we made in the second quarter executing our commercial strategy, advancing our clinical initiatives, and beginning to deliver the significant operating leverage we expected,” said Glen French, President and Chief Executive Officer of Pulmonx. “With a fully staffed US sales leadership team, a more focused global commercial team, and a realigned cost structure, we are confident in our ability to return to year-over-year revenue growth and drive meaningful operating leverage while advancing our longer-term strategic priorities.”
Second Quarter 2026 Financial Results
Total worldwide revenue in the second quarter of 2026 was
Gross profit in the second quarter of 2026 was
Operating expenses in the second quarter of 2026 were
Net loss in the second quarter of 2026 was
Adjusted EBITDA loss in the second quarter of 2026 was
Cash and cash equivalents totaled
2026 Financial Outlook
Pulmonx continues to expect revenue for the full year 2026 to be in the range of
The Company now expects gross margin for the full year 2026 to be approximately
Pulmonx now expects total operating expenses for the full year 2026 to fall within the range of
The Company continues to expect cash, cash equivalents, and marketable securities to decrease by approximately
Webcast and Conference Call Details
Pulmonx will host a conference call today, July 29, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its second quarter financial results. A live webcast of the conference call will be available on the Investor Relations section of the Company’s website at https://investors.pulmonx.com/. The webcast will be archived on the website following the completion of the call.
Use of Non-GAAP Financial Measures
To supplement Pulmonx’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, Pulmonx provides certain non-GAAP financial measures in this release as supplemental financial metrics. Non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results, may provide a more complete understanding of factors and trends affecting Pulmonx’s business.
Constant currency calculations show reported current period revenues as if the foreign exchange rates remain the same as those in effect in the comparable prior year period. Pulmonx uses results on a constant currency basis as one measure to evaluate its performance. Pulmonx calculates constant currency by calculating current-year results using foreign currency exchange rates from the applicable comparable period in the prior year. Pulmonx generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. Pulmonx believes the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand its operating results and evaluate its performance in comparison to prior periods. Pulmonx generally uses constant currency to facilitate management’s financial and operational decision-making, including evaluation of Pulmonx’s historical operating results.
The Company defines Adjusted EBITDA as earnings before interest income or expense, taxes, depreciation and amortization and stock-based compensation and may also exclude certain non-recurring, irregular or one-time items not reflective of our ongoing core business operations, such as impairment charges. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. Further, management uses adjusted EBITDA for strategic and annual operating planning. We believe these non-GAAP financial measures are useful as a supplement in evaluating our ongoing operational performance and enhancing an overall understanding of our past financial performance.
Reconciliation of these non-GAAP financial measures to the most comparable GAAP measures is set forth in the tables below.
The non-GAAP financial measures used by Pulmonx should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because non-GAAP financial measures exclude the effect of items that increase or decrease the Company’s reported results of operations, management strongly encourages investors to review, when they become available, the Company’s consolidated financial statements and publicly filed reports in their entirety. The Company’s definition of non-GAAP measures may differ from similarly titled measures used by others.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect our strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding our ability to drive improvements in revenue growth, execute against our strategic priorities, and deliver meaningful operating leverage, our possible or assumed future results of operations, including long-term outlook, descriptions of our revenues, total operating expenses, gross margin, balances of cash, cash equivalents, and marketable securities, profitability, guidance for full year 2026, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Pulmonx’s public filings with the Securities and Exchange Commission (“SEC”), including the Quarterly Report on Form 10-Q filed with the SEC on May 4, 2026, available at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, we undertake no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX® Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr® Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, LungTraX®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Investor Contact
Brian Johnston or Webb Campbell
Gilmartin Group
investors@pulmonx.com
| Pulmonx Corporation Consolidated Statements of Operations (in thousands, except share and per share data) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | 22,756 | $ | 23,859 | $ | 43,342 | $ | 46,397 | ||||||||
| Cost of goods sold | 5,014 | 6,655 | 9,556 | 12,851 | ||||||||||||
| Gross profit | 17,742 | 17,204 | 33,786 | 33,546 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 5,034 | 5,306 | 9,933 | 10,062 | ||||||||||||
| Selling, general and administrative | 21,765 | 26,702 | 45,866 | 52,851 | ||||||||||||
| Total operating expenses | 26,799 | 32,008 | 55,799 | 62,913 | ||||||||||||
| Loss from operations | (9,057 | ) | (14,804 | ) | (22,013 | ) | (29,367 | ) | ||||||||
| Interest income | 329 | 723 | 679 | 1,587 | ||||||||||||
| Interest expense | (1,218 | ) | (799 | ) | (2,194 | ) | (1,580 | ) | ||||||||
| Other (expense) income, net | (1 | ) | (116 | ) | 76 | 51 | ||||||||||
| Net loss before tax | (9,947 | ) | (14,996 | ) | (23,452 | ) | (29,309 | ) | ||||||||
| Income tax expense | 133 | 177 | 282 | 312 | ||||||||||||
| Net loss | $ | (10,080 | ) | $ | (15,173 | ) | $ | (23,734 | ) | $ | (29,621 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.24 | ) | $ | (0.38 | ) | $ | (0.56 | ) | $ | (0.74 | ) | ||||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 42,468,762 | 40,429,655 | 42,184,793 | 40,193,469 | ||||||||||||
| Pulmonx Corporation Condensed Consolidated Balance Sheets (in thousands) (Unaudited) | ||||||||
| June 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 55,843 | $ | 69,751 | ||||
| Restricted cash | 259 | 258 | ||||||
| Accounts receivable, net | 12,247 | 12,072 | ||||||
| Inventory | 16,390 | 15,845 | ||||||
| Prepaid expenses and other current assets | 3,394 | 3,758 | ||||||
| Total current assets | 88,133 | 101,684 | ||||||
| Long-term inventory | 3,803 | 3,604 | ||||||
| Property and equipment, net | 1,885 | 2,220 | ||||||
| Goodwill | 2,333 | 2,333 | ||||||
| Right of use assets | 17,267 | 18,028 | ||||||
| Other long-term assets | 1,311 | 1,422 | ||||||
| Total assets | $ | 114,732 | $ | 129,291 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 4,675 | $ | 3,905 | ||||
| Accrued liabilities | 14,070 | 14,556 | ||||||
| Income taxes payable | 264 | 263 | ||||||
| Deferred revenue | 16 | 18 | ||||||
| Short-term debt | 103 | 106 | ||||||
| Current lease liabilities | 1,277 | 1,210 | ||||||
| Total current liabilities | 20,405 | 20,058 | ||||||
| Deferred tax liability | 62 | 69 | ||||||
| Long-term lease liabilities | 17,403 | 18,059 | ||||||
| Long-term debt | 37,428 | 36,989 | ||||||
| Common stock warrant liability | 238 | — | ||||||
| Total liabilities | 75,536 | 75,175 | ||||||
| Stockholders' equity | ||||||||
| Common stock | 43 | 42 | ||||||
| Additional paid-in capital | 582,396 | 573,272 | ||||||
| Accumulated other comprehensive income | 2,049 | 2,360 | ||||||
| Accumulated deficit | (545,292 | ) | (521,558 | ) | ||||
| Total stockholders' equity | 39,196 | 54,116 | ||||||
| Total liabilities and stockholders' equity | $ | 114,732 | $ | 129,291 | ||||
| Pulmonx Corporation Reconciliation of Reported Revenue % Change to Constant Currency Revenue % Change (in thousands, except percentages) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | ||||||||||||||||
| 2026 | 2025 | % Change | FX Impact % | Constant Currency % Change | ||||||||||||
| United States | $ | 14,176 | $ | 14,731 | (3.8 | )% | — | % | (3.8 | )% | ||||||
| International | 8,580 | 9,128 | (6.0 | )% | 3.0 | % | (9.0 | )% | ||||||||
| Total | $ | 22,756 | $ | 23,859 | (4.6 | )% | 1.2 | % | (5.8 | )% | ||||||
| Three Months Ended June 30, | ||||||||||||||||
| 2026 | 2025 | % Change | FX Impact % | Constant Currency % Change | ||||||||||||
| International | $ | 8,580 | $ | 9,128 | (6.0 | )% | 3.0 | % | (9.0 | )% | ||||||
| less China | — | (1,484 | ) | (100.0 | )% | — | % | (100.0 | )% | |||||||
| International excluding China | $ | 8,580 | $ | 7,644 | 12.2 | % | 3.6 | % | 8.6 | % | ||||||
| Six Months Ended June 30, | ||||||||||||||||
| 2026 | 2025 | % Change | FX Impact % | Constant Currency % Change | ||||||||||||
| United States | $ | 27,431 | $ | 28,952 | (5.3 | )% | — | % | (5.3 | )% | ||||||
| International | 15,911 | 17,445 | (8.8 | )% | 6.1 | % | (14.9 | )% | ||||||||
| Total | $ | 43,342 | $ | 46,397 | (6.6 | )% | 2.3 | % | (8.9 | )% | ||||||
| Six Months Ended June 30, | ||||||||||||||||
| 2026 | 2025 | % Change | FX Impact % | Constant Currency % Change | ||||||||||||
| International | $ | 15,911 | $ | 17,445 | (8.8 | )% | 6.1 | % | (14.9 | )% | ||||||
| less China | — | (3,779 | ) | (100.0 | )% | — | % | (100.0 | )% | |||||||
| International excluding China | $ | 15,911 | $ | 13,666 | 16.4 | % | 7.8 | % | 8.6 | % | ||||||
| Pulmonx Corporation Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA (in thousands) (Unaudited) | |||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||
| GAAP Net loss | $ | (10,080 | ) | $ | (15,173 | ) | $ | (23,734 | ) | $ | (29,621 | ) | |
| Depreciation and amortization | 222 | 299 | 442 | 577 | |||||||||
| Stock-based compensation | 3,698 | 6,214 | 7,834 | 11,826 | |||||||||
| Interest (income)/expense, net | 889 | 76 | 1,515 | (7 | ) | ||||||||
| Provision for income taxes | 133 | 177 | 282 | 312 | |||||||||
| Adjusted EBITDA | $ | (5,138 | ) | $ | (8,407 | ) | $ | (13,661 | ) | $ | (16,913 | ) | |
